GLP-1 patches: do they work, and what is actually in them?

Before you read. This guide is educational and does not replace your prescriber, your pharmacist, a diagnosis, or emergency care. It does not tell you which product to buy or which medicine to take, and it does not advise starting, stopping, or changing the dose of anything. If you are already taking a GLP-1 medicine, do not change it because of a page on the internet.

Quick answer

No product sold as a GLP-1 patch delivers an approved GLP-1 medicine. Semaglutide weighs 4,113.58 daltons; intact skin generally stops molecules above about 500. Every approved GLP-1 drug is either a subcutaneous injection or a swallowed tablet. Patches are sold as supplements, which need no premarket approval.

Open Takely in your browser

Do GLP-1 patches work?

Not in the way the product pages imply, and the reason is not a matter of opinion or of pending research. It is a size problem, and the numbers are public.

A GLP-1 patch, as sold, promises the effects of a GLP-1 receptor agonist without a needle. To deliver that, something would have to move a GLP-1 receptor agonist across the outermost layer of your skin — the stratum corneum — and into circulation, in a controlled dose, through an adhesive square. Nothing on the market does this, nothing has been approved to do this, and the molecules involved are, on the published evidence, far too large for the passive route these patches rely on.

That leaves a straightforward question, which the rest of this page answers: if there is no GLP-1 in the patch, what is in it?

The size problem: 4,113 daltons against a 500-dalton ceiling

Two numbers do most of the work here.

The first comes from the FDA label. In the DESCRIPTION section for oral semaglutide, the molecular formula is given as C187H291N45O59, with a molecular weight of 4,113.58 g/mol. Semaglutide is a peptide — a chain of amino acids — not a small molecule.

The second comes from dermatology. In 2000, Bos and Meinardi published what is now known as the 500 Dalton rule: compounds must generally be under 500 daltons to cross the corneal layer of human skin. Their argument rested on three observations, and the third is the one that matters most here — "All known topical drugs used in transdermal drug-delivery systems are under 500 Dalton." Nicotine, scopolamine, oestradiol, fentanyl, rivastigmine: the entire established patch pharmacopoeia sits under that ceiling.

Semaglutide is roughly eight times the ceiling. Tirzepatide, liraglutide, dulaglutide and exenatide are peptides too, in the same weight class or heavier. This is why the injection exists in the first place: not because manufacturers prefer needles, but because a peptide that large has essentially two ways into the bloodstream — bypass the barrier with a needle, or engineer a very specific chemical trick to sneak a small fraction of it across a mucous membrane.

An adhesive patch does neither.

Route	Delivers a GLP-1 receptor agonist?	Approved products
Subcutaneous injection	Yes	Ozempic, Wegovy, Mounjaro, Byetta, liraglutide products
Oral tablet	Yes, with an absorption enhancer or a small-molecule design	Rybelsus, Ozempic tablets, Wegovy tablets, Foundayo
Transdermal patch	No approved product	None
Topical cream or gel	No approved product	None

That table was built by listing every GLP-1 receptor agonist product on DailyMed, the US National Library of Medicine's label repository, and reading off its dosage form and route. Two routes appear: injection and tablet. No transdermal, topical, or patch formulation appears at all.

So what is actually in a GLP-1 patch?

Not a GLP-1 receptor agonist — because if it were, the product would be a drug, and it would need approval it does not have.

Products marketed as GLP-1 patches are, almost without exception, sold as dietary supplements or as cosmetic-adjacent adhesives. The NIH Office of Dietary Supplements states the regulatory position plainly: "Unlike drugs, dietary supplements do not require premarket review or approval by FDA." The same fact sheet notes that manufacturers themselves are responsible for determining that their products are safe and their label claims truthful, and that for weight-loss supplements generally, "Little is known about whether weight loss supplements are effective, but some supplements have been associated with the potential for physical harm."

So the ingredient list, not the marketing, is the thing to read. In practice a patch sold under GLP-1 branding contains some combination of botanical extracts, caffeine, vitamins, or nothing pharmacologically active at all. The word "GLP-1" on the box is doing a different job than you might assume: it usually describes an intention ("supports your body's own GLP-1") rather than a contents claim. Those are very different sentences, and only one of them is a promise.

Two more categories worth naming, because they get conflated with patches:

"Natural GLP-1" supplements. Same regulatory status as the patches — no premarket approval, no requirement to demonstrate effect before sale. Whatever a berberine or fibre product does, it is not the pharmacology of a GLP-1 receptor agonist, and it should not be compared to one on a dose-for-dose basis.
Compounded and imported "GLP-1" products. These are a distinct and more serious problem. Unlike patches, some of them really do contain peptides — of unverified identity, purity, and concentration. The FDA has publicly documented dosing errors, unapproved salt forms, and adverse events including hospitalisations tied to unapproved versions of semaglutide and tirzepatide. A product being real is not the same as a product being safe.

If you got here because injections are the obstacle, there is a real answer — and it is not a patch. Oral GLP-1 tablets exist and are approved; they just come with a morning window instead of a needle. Takely times that window. Open Takely in your browser →

Why a tablet works when a patch cannot

This is the part that makes the patch claim collapse, because it shows how much engineering an alternative route actually takes.

Oral semaglutide does not simply survive the stomach. It is co-formulated with salcaprozate sodium (SNAC), an absorption enhancer. In Science Translational Medicine in 2018, Buckley and colleagues showed what SNAC does: absorption of semaglutide "takes place in the stomach, is confined to an area in close proximity to the tablet surface," and SNAC "protects against enzymatic degradation via local buffering actions and only transiently enhances absorption."

Read that carefully. The tablet does not make the stomach permeable to peptides in general. It creates a small, temporary, local pocket of favourable conditions — a few square millimetres of stomach lining, for a few minutes, right where the tablet is dissolving. Even so, the label puts estimated absolute bioavailability at 0.4% to 1% for Rybelsus and 1% to 2% for Ozempic tablets. Around ninety-nine per cent of the dose does not make it into circulation.

That is what it took to open a non-injection route for this molecule: a purpose-built excipient, a specific anatomical site, a transient window, and a dose calibrated around a yield of roughly one per cent.

A patch has none of that. It has adhesive, a backing layer, and skin that evolved specifically to keep large molecules out.

The routes that actually exist

If the reason you searched for a patch is that you would rather not inject, the honest news is good: the non-injection route exists, it is approved, and it is a tablet.

Oral semaglutide. Rybelsus and Ozempic tablets for type 2 diabetes; Wegovy tablets for chronic weight management and cardiovascular risk reduction. Same molecule as the pens, delivered by the SNAC mechanism above. If you are trying to work out which of these is which, see which oral semaglutide is which.
Orforglipron. A small-molecule GLP-1 receptor agonist — not a peptide — which is why it can be a plain film-coated tablet without an absorption enhancer. See the first small-molecule GLP-1 pill.
The pens. Still the majority of the category, still the reference point for most of the outcome data. If you want the honest trade-offs rather than the marketing version, we put the pill and the injection compared side by side.

Which of these, if any, belongs on your prescription is a clinical decision. This page cannot make it and neither can a product page selling adhesive squares.

What the pill asks in exchange

The tablet route is not free. It swaps a weekly needle for a daily rule, and the rule is unforgiving because it is a direct consequence of the absorption mechanism above.

The label for oral semaglutide is specific: take one tablet once daily on an empty stomach in the morning with no more than 4 ounces of water, swallow it whole — "Do not split, crush, chew or dissolve in any solution" — and wait at least 30 minutes before eating food, drinking other beverages, or taking other oral medications.

Thirty minutes sounds trivial until it is 6:40 a.m. and the coffee is already poured. That single window is where the tablet route mostly fails in real life — not through side effects, not through motivation, but through an ordinary morning. We walk it in the 30-minute wait, step by step, and if you would rather not hold it in your head at all, time the window and log the dose.

How to read a GLP-1 patch product page

If you are still weighing a specific product, four questions settle most of it quickly.

Does the ingredient list name a GLP-1 receptor agonist? Semaglutide, tirzepatide, liraglutide, exenatide, orforglipron. If none appears, the product is not delivering one, whatever the brand name suggests.
Is it labelled as a dietary supplement? If yes, no regulator reviewed it for effectiveness before it went on sale.
**Does the page cite a trial of this product, or a trial of a prescription drug?** Citing Ozempic's outcome data next to a patch is not evidence about the patch.
Does it say "supports" rather than "contains"? "Supports GLP-1" is a claim about intention. "Contains semaglutide" would be a claim about contents — and would make it an unapproved drug.

If a product ever does cross this line legitimately, it will arrive the way approved medicines arrive: with trials, a label, a route of administration on that label, and a regulator's name attached. Until then, the absence of those things is the answer.

Frequently asked questions

Do GLP-1 patches work for weight loss?

No approved GLP-1 patch exists, and no product sold as one delivers an approved GLP-1 receptor agonist. Since these products are marketed as supplements, they were not reviewed for effectiveness before sale. Any effect claimed for a specific patch is a claim about that patch, and should be judged on evidence about that patch — not on trial data borrowed from prescription drugs.

Is there an FDA-approved GLP-1 patch?

No. Listing every GLP-1 receptor agonist product on DailyMed and reading off the dosage form gives two routes: injection (subcutaneous) and tablet (oral). No transdermal, topical, or patch product appears.

Why can't semaglutide be delivered through the skin?

Semaglutide's molecular weight is 4,113.58 daltons. The widely cited 500 Dalton rule holds that compounds must generally be under 500 daltons to cross the stratum corneum, and notes that every drug used in an established transdermal delivery system is under that figure. Semaglutide is about eight times over it.

What is actually in a GLP-1 patch?

Whatever the ingredient panel says — typically botanical extracts, caffeine, or vitamins. Because these products are sold as dietary supplements, the NIH Office of Dietary Supplements notes they "do not require premarket review or approval by FDA," and the manufacturer alone is responsible for the truth of the label claims.

Are "natural GLP-1" supplements different from GLP-1 patches?

Only in the delivery format. Both are sold under the same regulatory framework, without premarket approval, and neither contains a GLP-1 receptor agonist. A supplement claiming to support your body's own GLP-1 is making a different claim from a medicine that is a GLP-1 receptor agonist, even when the packaging blurs them.

Is there a non-injection GLP-1 that actually works?

Yes — swallowed tablets. Oral semaglutide (Rybelsus, Ozempic tablets, Wegovy tablets) uses the SNAC absorption enhancer to be absorbed in the stomach; orforglipron is a small molecule that does not need one. Both are approved medicines with labels, indications, and prescribers attached.

Could a GLP-1 patch be approved in future?

Delivering a peptide through skin would need active technology — microneedles or another barrier-bypassing method — rather than passive diffusion through an adhesive. Research into such systems exists, but no such product is approved, and nothing currently sold as a GLP-1 patch works that way.

Are compounded or imported GLP-1 products safer than patches?

Not automatically, and in some respects the risk profile is worse. FDA has publicly described concerns with unapproved versions of semaglutide and tirzepatide, including dosing errors, unapproved salt forms, and adverse events requiring hospitalisation. A product that genuinely contains a peptide of unknown purity is a different hazard from an inert sticker, not a lesser one.

Primary sources and further reading

Labels and regulatory positions are revised. Everything on this page was checked against the sources above on 11 August 2026. Ask your clinician or pharmacist about your own situation.